Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
NPJ Vaccines|March 22, 2018
Vaccination route can significantly alter the innate lymphoid cell subsets: a feedback between IL-13 and IFN-γZheyi Li, Ronald J Jackson, Charani RanasingheVirology|September 28, 2014
Different HIV pox viral vector-based vaccines and adjuvants can induce unique antigen presenting cells that modulate CD8 T cell avidityShubhanshi Trivedi, Ronald J Jackson, Charani RanasingheMethods in Molecular Biology (Clifton, N.J.)|April 10, 2014
Progresses in DNA-based heterologous prime-boost immunization strategiesRonald J Jackson, David B Boyle, Charani RanasingheJournal of Immunology (Baltimore, Md. : 1950)|August 7, 2009
IL-12p40 and IL-18 play pivotal roles in orchestrating the cell-mediated immune response to a poxvirus infectionYang Wang, Geeta Chaudhri, Ronald J Jackson, et al.Vaccine|August 25, 2014
Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacyRonald J Jackson, Matthew Worley, Shubhanshi Trivedi, et al.Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|December 11, 2014
IL-17A expression in HIV-specific CD8 T cells is regulated by IL-4/IL-13 following HIV-1 prime-boost immunizationJayashree Ravichandran, Ronald J Jackson, Shubhanshi Trivedi, et al.The Journal of General Virology|January 6, 2017
Recombinant fowlpox virus vector-based vaccines: expression kinetics, dissemination and safety profile following intranasal deliveryDavid G Townsend, Shubhanshi Trivedi, Ronald J Jackson, et al.Cytokine & Growth Factor Reviews|August 28, 2014
IL-4 and IL-13 receptors: Roles in immunity and powerful vaccine adjuvantsCharani Ranasinghe, Shubhanshi Trivedi, Danushka K Wijesundara, et al.Mucosal Immunology|May 24, 2012
Role of novel type I interferon epsilon in viral infection and mucosal immunityYang Xi, Stephanie L Day, Ronald J Jackson, et al.Immunology and Cell Biology|October 20, 2010
Human immunodeficiency virus-1 vaccine design: where do we go now?Danushka K Wijesundara, Ronald J Jackson, Ian A Ramshaw, et al.Pageof 2